The most significant Alemtuzumab Multiple Sclerosis trials have been in Canada.  There, an important trial has shown that Alemtuzumab MS treatments kept relapses from occurring in more than 70% of the participants.  The study goes on to report that not only did these patients have no relapses, but they showed “no clinical disease activity.  This is statistically much better than patients that were treated with subcutaneous interferon Beta-1a.  Interferon Beta – 1A, also known as Rebif only showed a 48.5% relapse free rate while the Alemtuzumab Multiple Sclerosis treated patients had a relapse free rate of about 90%.  The study was conducted in Toronto, Canada.  The patients got 5 injections in the first week of the study and then 3 more on consecutive days a year later.

Outcomes for the Alemtuzumab MS treatment was the same even when dosage varied.

The Alemtuzumab (MS) Multiple Sclerosis study was done …